tradingkey.logo

Karyopharm Therapeutics Inc <KPTI.OQ> expected to post a loss of $4.18 a share - Earnings Preview

ReutersMay 2, 2025 1:09 PM
  • Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to show a rise in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

  • The Newton Massachusetts-based company is expected to report a 6.4% increase in revenue to $35.242 million from $33.13 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $4.18 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $54.00​, above​ its last closing price of $6.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-4.32

-3.92

-3.60

Beat

8.2

Sep. 30 2024

-3.76

-3.94

-3.90

Beat

1.1

Jun. 30 2024

-4.31

-4.48

2.25

Beat

150.2​

Mar. 31 2024

-4.93

-5.01

-4.80

Beat

4.2

​​Dec. 31 2023

-4.68

-4.65

-5.40

Missed

-16.2

Sep. 30 2023

-4.26

-4.20

-4.50

Missed

-7.1​

Jun. 30 2023

-5.26

-5.13

-4.35

Beat

15.3

Mar. 31 2023

-5.43

-5.52

-4.50

Beat

18.5

This summary was machine generated May 2 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI